$DRIO
DarioHealth Corp.

2021 Q4 Form 10-K Financial Statement

#000155837022004018 Filed on March 22, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $6.028M $20.51M $2.080M
YoY Change 189.81% 170.76% 15.56%
Cost Of Revenue $5.480M $12.44M $1.530M
YoY Change 258.17% 145.78% 59.38%
Gross Profit $548.0K $3.963M $550.0K
YoY Change -0.36% 57.7% -34.52%
Gross Profit Margin 9.09% 19.32% 26.44%
Selling, General & Admin $16.90M $63.24M $8.190M
YoY Change 106.31% 126.01% 95.93%
% of Gross Profit 3083.39% 1595.71% 1489.09%
Research & Development $5.316M $17.22M $1.420M
YoY Change 274.37% 288.43% 69.05%
% of Gross Profit 970.07% 434.49% 258.18%
Depreciation & Amortization $719.0K $282.0K $50.00K
YoY Change 1338.0% 48.42% 25.0%
% of Gross Profit 131.2% 7.12% 9.09%
Operating Expenses $22.21M $80.46M $9.610M
YoY Change 131.14% 148.2% 91.43%
Operating Profit -$21.67M -$76.49M -$9.060M
YoY Change 139.13% 155.81% 116.75%
Interest Expense $135.0K -$151.0K $70.00K
YoY Change 92.86% -129.61% 600.0%
% of Operating Profit
Other Income/Expense, Net -$24.00K -$235.0K -$10.00K
YoY Change 140.0% -151.31%
Pretax Income -$21.55M -$76.73M -$9.000M
YoY Change 139.49% 160.58% 115.83%
Income Tax $32.00K $32.00K
% Of Pretax Income
Net Earnings -$21.59M -$76.76M -$9.000M
YoY Change 139.84% 160.69% 115.83%
Net Earnings / Revenue -358.1% -374.21% -432.69%
Basic Earnings Per Share $4.07
Diluted Earnings Per Share -$1.215M $4.07 -$969.8K
COMMON SHARES
Basic Shares Outstanding 16.58M 16.59M
Diluted Shares Outstanding 16.59M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.00M $36.00M $28.80M
YoY Change 25.0% 25.09% 39.81%
Cash & Equivalents $35.81M $35.81M $28.59M
Short-Term Investments $192.0K $192.0K $200.0K
Other Short-Term Assets $76.00K $1.667M $80.00K
YoY Change -5.0% 16.57%
Inventory $6.228M $6.228M $2.293M
Prepaid Expenses
Receivables $1.310M $1.310M $100.0K
Other Receivables $2.067M $400.0K $3.000M
Total Short-Term Assets $45.61M $45.61M $34.13M
YoY Change 33.63% 33.62% 49.03%
LONG-TERM ASSETS
Property, Plant & Equipment $702.0K $989.0K $576.0K
YoY Change 21.88% -7.57% -58.86%
Goodwill $41.64M $0.00
YoY Change
Intangibles $12.46M
YoY Change
Long-Term Investments
YoY Change
Other Assets $77.00K $77.00K $200.0K
YoY Change -61.5% -63.33% 0.0%
Total Long-Term Assets $55.17M $55.17M $1.279M
YoY Change 4213.21% 4209.84% -24.76%
TOTAL ASSETS
Total Short-Term Assets $45.61M $45.61M $34.13M
Total Long-Term Assets $55.17M $55.17M $1.279M
Total Assets $100.8M $100.8M $35.41M
YoY Change 184.61% 184.58% 43.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.109M $5.109M $2.500M
YoY Change 104.36% 106.01% 47.06%
Accrued Expenses $4.398M $8.072M $880.0K
YoY Change 399.77% 142.4% 193.33%
Deferred Revenue $1.195M $1.224M
YoY Change -2.37%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.20M $14.38M $7.034M
YoY Change 116.11% 104.5% 35.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $846.0K $846.0K $200.0K
YoY Change 323.0% 284.55% -60.0%
Total Long-Term Liabilities $21.00K $846.0K $222.0K
YoY Change -90.54% 284.55% -55.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.20M $14.38M $7.034M
Total Long-Term Liabilities $21.00K $846.0K $222.0K
Total Liabilities $15.22M $15.22M $7.256M
YoY Change 109.79% 109.67% 27.3%
SHAREHOLDERS EQUITY
Retained Earnings -$222.0M -$143.2M
YoY Change 54.99%
Common Stock $2.000K $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $85.55M $85.55M $28.15M
YoY Change
Total Liabilities & Shareholders Equity $100.8M $100.8M $35.41M
YoY Change 184.61% 184.58% 43.93%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$21.59M -$76.76M -$9.000M
YoY Change 139.84% 160.69% 115.83%
Depreciation, Depletion And Amortization $719.0K $282.0K $50.00K
YoY Change 1338.0% 48.42% 25.0%
Cash From Operating Activities -$15.14M -$50.41M -$6.760M
YoY Change 123.91% 184.22% 136.36%
INVESTING ACTIVITIES
Capital Expenditures -$68.00K $261.0K -$50.00K
YoY Change 36.0% 121.19% 150.0%
Acquisitions
YoY Change
Other Investing Activities -$376.0K -$7.873M -$1.500M
YoY Change -74.93% 424.87%
Cash From Investing Activities -$444.0K -$8.134M -$1.550M
YoY Change -71.35% 401.48% 15400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $64.88M
YoY Change 135.51%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 65.77M 0.000
YoY Change 138.73% -100.0%
NET CHANGE
Cash From Operating Activities -15.14M -50.41M -6.760M
Cash From Investing Activities -444.0K -8.134M -1.550M
Cash From Financing Activities 0.000 65.77M 0.000
Net Change In Cash -15.58M 7.223M -8.310M
YoY Change 87.48% -11.81% -152.53%
FREE CASH FLOW
Cash From Operating Activities -$15.14M -$50.41M -$6.760M
Capital Expenditures -$68.00K $261.0K -$50.00K
Free Cash Flow -$15.07M -$50.67M -$6.710M
YoY Change 124.56% 183.8% 136.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Trading Symbol
TradingSymbol
DRIO
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.07
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.01
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16591718
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5963305
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001533998
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8119493
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
11927
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16573420
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
15823
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-37704
CY2021 dei Entity Registrant Name
EntityRegistrantName
DARIOHEALTH CORP.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2973162
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
18 W. 18th St.
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
825000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
846000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
222000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10011
CY2021 dei City Area Code
CityAreaCode
972
CY2021 dei Local Phone Number
LocalPhoneNumber
4 770-6377
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
576000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12460000
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
307551746
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21814967
CY2021 dei Auditor Firm
AuditorFirmId
1281
CY2021 dei Auditor Name
AuditorName
KOST FORER GABBAY & KASIERER
CY2021 dei Auditor Location
AuditorLocation
Tel-Aviv, Israel
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35808000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28590000
CY2021Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
192000
CY2020Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
187000
CY2021Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1310000
CY2020Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
124000
CY2021Q4 us-gaap Inventory Net
InventoryNet
6228000
CY2020Q4 us-gaap Inventory Net
InventoryNet
2293000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2067000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2934000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
45605000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
34128000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
20000
CY2020Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
20000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
287000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
498000
CY2021Q4 drio Long Term Assets Noncurrent
LongTermAssetsNoncurrent
57000
CY2020Q4 drio Long Term Assets Noncurrent
LongTermAssetsNoncurrent
185000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
702000
CY2021Q4 us-gaap Goodwill
Goodwill
41640000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
55166000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
1279000
CY2021Q4 us-gaap Assets
Assets
100771000
CY2020Q4 us-gaap Assets
Assets
35407000
CY2021Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
5109000
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
2480000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1195000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1224000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
266000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
310000
CY2021Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
7806000
CY2020Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
3020000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14376000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7034000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
222000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16573420
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8119493
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
11927
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
15823
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
307561000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
171399000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222014000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143248000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
85549000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28151000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
100771000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35407000
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
20513000
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7576000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12444000
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5063000
CY2021 drio Amortization Of Acquired Technology And Inventory
AmortizationOfAcquiredTechnologyAndInventory
4106000
CY2021 us-gaap Gross Profit
GrossProfit
3963000
CY2020 us-gaap Gross Profit
GrossProfit
2513000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17219000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4433000
CY2021 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
39706000
CY2020 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
15227000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23532000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12756000
CY2021 us-gaap Operating Expenses
OperatingExpenses
80457000
CY2020 us-gaap Operating Expenses
OperatingExpenses
32416000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-76494000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-29903000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-235000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
458000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-76729000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29445000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-76761000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-29445000
CY2021 drio Deemed Dividend
DeemedDividend
-2005000
CY2020 drio Deemed Dividend
DeemedDividend
-3658000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-78766000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33103000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.07
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.01
CY2021 us-gaap Payments To Acquire Loans Receivable
PaymentsToAcquireLoansReceivable
400000
CY2020 us-gaap Payments To Acquire Loans Receivable
PaymentsToAcquireLoansReceivable
1500000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16591718
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5963305
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
18894000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1003000
CY2020 drio Warrants Issued During Period Exercise Of Repriced Warrants Value
WarrantsIssuedDuringPeriodExerciseOfRepricedWarrantsValue
1088000
CY2020 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1993000
CY2020 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
4913000
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1487000
CY2020 drio Stock Issued During Period Value Common Stock
StockIssuedDuringPeriodValueCommonStock
26460000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1758000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-29445000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28151000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
152000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
256000
CY2021 drio Warrants Issued During Period Exercise Of Repriced Warrants Value
WarrantsIssuedDuringPeriodExerciseOfRepricedWarrantsValue
633000
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
4626000
CY2021 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
303000
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
6817000
CY2021 drio Stock Issued During Period Value Common Stock
StockIssuedDuringPeriodValueCommonStock
64877000
CY2021 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
43422000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
13073000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-76761000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
85549000
CY2021 us-gaap Profit Loss
ProfitLoss
-76761000
CY2020 us-gaap Profit Loss
ProfitLoss
-29445000
CY2021 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
24971000
CY2020 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
11102000
CY2021 us-gaap Depreciation
Depreciation
282000
CY2020 us-gaap Depreciation
Depreciation
190000
CY2021 drio Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-211000
CY2020 drio Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-267000
CY2021 drio Amortization Of Inventory Set Up
AmortizationOfInventorySetUp
1140000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3035000
CY2021 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
351000
CY2020 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-548000
CY2021 drio Increase Decrease In Other Accounts Receivable And Prepaid Expenses And Long Term Assets
IncreaseDecreaseInOtherAccountsReceivableAndPrepaidExpensesAndLongTermAssets
-16000
CY2020 drio Increase Decrease In Other Accounts Receivable And Prepaid Expenses And Long Term Assets
IncreaseDecreaseInOtherAccountsReceivableAndPrepaidExpensesAndLongTermAssets
-1152000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2230000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
879000
CY2021 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1080000
CY2020 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
824000
CY2021 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-865000
CY2020 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1048000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-157000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-245000
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-240000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-503000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50409000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17736000
CY2020 drio Payments For Proceeds From Acquire Leases Held For Investment
PaymentsForProceedsFromAcquireLeasesHeldForInvestment
4000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
261000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
118000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1622000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64877000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8134000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27548000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
633000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
256000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
65766000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27548000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7223000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
8190000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28725000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20535000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35948000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28725000
CY2021 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-76494000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50409000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35808000
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">a.     Use of estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 72pt;">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires the Company’s management to make judgments, assumptions and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates, and such differences may be material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 72pt;">Management believes the Company’s critical accounting policies and estimates are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2021Q4 drio Short Term Restricted Bank Deposits Collateral For Rent
ShortTermRestrictedBankDepositsCollateralForRent
127000
CY2020Q4 drio Short Term Restricted Bank Deposits Collateral For Rent
ShortTermRestrictedBankDepositsCollateralForRent
123000
CY2021Q4 drio Short Term Restricted Bank Deposits Collateral For Credit Payment
ShortTermRestrictedBankDepositsCollateralForCreditPayment
65000
CY2020Q4 drio Short Term Restricted Bank Deposits Collateral For Credit Payment
ShortTermRestrictedBankDepositsCollateralForCreditPayment
64000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35808000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28590000
CY2021Q4 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
140000
CY2020Q4 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
135000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35948000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28725000
CY2021 us-gaap Inventory Write Down
InventoryWriteDown
73000
CY2020 us-gaap Inventory Write Down
InventoryWriteDown
99000
CY2021Q4 us-gaap Inventory Net
InventoryNet
6228000
CY2020Q4 us-gaap Inventory Net
InventoryNet
2293000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">k.     Concentrations of credit risk:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 72pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, short-term restricted bank deposits and trade receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">NOTE 2:-     SIGNIFICANT ACCOUNTING POLICIES (Cont.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 72pt;">All of the cash and cash equivalents and short-term restricted bank deposits of the Company and its Subsidiaries are invested in deposits and current accounts with major U.S. and Israeli banks. Such cash and cash equivalents and short-term restricted bank deposits may be in excess of insured limits and are not insured in other jurisdictions. Generally, cash and cash equivalents and short-term restricted bank deposits may be redeemed and therefore a minimal credit risk exists with respect to these deposits and investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 72pt;">The Company’s trade receivables are derived mainly from sales to distributers and to end-users world-wide. The Company performs ongoing credit evaluations of its customers. An allowance for doubtful accounts is determined with respect to those specific amounts that the Company has determined to be doubtful of collection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 72pt;">The Company had no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</p>
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7155744
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6636437
CY2021 drio Percentage Of Monthly Deposits Behalf Of Insurance Companies
PercentageOfMonthlyDepositsBehalfOfInsuranceCompanies
0.0833
CY2021 us-gaap Severance Costs1
SeveranceCosts1
870000
CY2020 us-gaap Severance Costs1
SeveranceCosts1
387000
CY2021 drio Defined Contribution Plan Maximum Annual Contributions Per Employee Amount Over Fifty Years Of Age
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmountOverFiftyYearsOfAge
26000
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1591000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1354000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
76000
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
714000
CY2020Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
377000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5514000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1916000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
80000
CY2021Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
400000
CY2020Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
1500000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2067000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2934000
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
20513000
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7576000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1224000
CY2021Q4 drio New Performance Obligations
NewPerformanceObligations
3633000
CY2021 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
-3662000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1195000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
287000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
344000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
415000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
8000
CY2021 us-gaap Lease Cost
LeaseCost
767000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0728
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
271000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
27000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
298000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
344000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
56000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1928000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1368000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1226000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
792000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
702000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
576000
CY2021 us-gaap Depreciation
Depreciation
282000
CY2020 us-gaap Depreciation
Depreciation
190000
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
15495000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3035000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12460000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3035000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
3905000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3905000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3845000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
805000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12460000
CY2020Q4 us-gaap Goodwill
Goodwill
0
CY2021 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
41640000
CY2021Q4 us-gaap Goodwill
Goodwill
41640000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3408000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2140000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4398000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
880000
CY2021Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
7806000
CY2020Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
3020000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29445000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.23
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.23
CY2021 drio Operating Loss Carryforwards Subject To Expiration
OperatingLossCarryforwardsSubjectToExpiration
30306000
CY2021 drio Operating Loss Carryforwards Not Subject To Expiration
OperatingLossCarryforwardsNotSubjectToExpiration
7120000
CY2021 drio Remaining Net Operating Losses
RemainingNetOperatingLosses
23186000
CY2021Q4 drio Percentage Of Income To Be Offset By Net Operating Loss Carry Forwards
PercentageOfIncomeToBeOffsetByNetOperatingLossCarryForwards
0.80
CY2021 drio Percentage Of Future Net Income That Can Be Offset By Net Operating Loss Carryforwards Under Cares Act
PercentageOfFutureNetIncomeThatCanBeOffsetByNetOperatingLossCarryforwardsUnderCaresAct
1
CY2021Q4 drio Deferred Tax Assets Operating Loss Carryforwards And Capital Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwardsAndCapitalLossCarryforwards
39328000
CY2020Q4 drio Deferred Tax Assets Operating Loss Carryforwards And Capital Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwardsAndCapitalLossCarryforwards
23326000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2654000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
912000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
320000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
197000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1426000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
43728000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
24435000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
41520000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
24435000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2208000
CY2021Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2208000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2208000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
17085000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21065000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-12471000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-55664000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-16974000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-76729000
CY2019Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
21375
CY2019Q4 drio Gross Proceeds From Issuance Of Preferred Stock And Preference Stock
GrossProceedsFromIssuanceOfPreferredStockAndPreferenceStock
21375000
CY2019Q4 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
18689000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2969266
CY2020Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
7.47
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
824689
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.4699
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31486
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.94
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
28591000
CY2020Q3 drio Shares Issuance Cost Net
SharesIssuanceCostNet
26460000
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
40545
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
256000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1273280
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
230452
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
230452
CY2020Q1 drio Class Of Warrant Or Right Aggregate With Shares Consideration
ClassOfWarrantOrRightAggregateWithSharesConsideration
161317
CY2020Q3 drio Class Of Warrant Or Right Aggregate With Shares Consideration
ClassOfWarrantOrRightAggregateWithSharesConsideration
161317
drio Deemed Dividend Related To Warrant Exchange Agreement
DeemedDividendRelatedToWarrantExchangeAgreement
599000
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
88889
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
88889
CY2020Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
13.00
CY2020Q3 drio Gross Proceeds From Private Placement
GrossProceedsFromPrivatePlacement
1156000
CY2020Q3 drio Shares Issuance Cost Net
SharesIssuanceCostNet
1088000
CY2020Q1 drio Stock Issued During Period Shares Non Qualified Stock Option Gross
StockIssuedDuringPeriodSharesNonQualifiedStockOptionGross
140000
CY2020Q1 drio Stock Issued During Period Shares Non Qualified Stock Option Gross
StockIssuedDuringPeriodSharesNonQualifiedStockOptionGross
140000
CY2020Q1 drio Stock Issued During Period Shares Non Qualified Performance Based Stock Option Gross
StockIssuedDuringPeriodSharesNonQualifiedPerformanceBasedStockOptionGross
90000
CY2020Q1 drio Stock Issued During Period Shares Non Qualified Performance Based Stock Option Gross
StockIssuedDuringPeriodSharesNonQualifiedPerformanceBasedStockOptionGross
90000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
973575
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.56
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y11M26D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5510000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1108073
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.32
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
40545
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
58947
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
43.90
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
103988
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.39
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1878168
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.04
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M15D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3861000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1744846
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
18.27
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y11M1D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
3655000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
590060
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
22.47
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y14D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2243000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.59
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.19
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
26067000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y1M24D
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24971000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11102000
CY2021 drio Bank Charges
BankCharges
84000
CY2020 drio Bank Charges
BankCharges
49000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-195000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
446000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
44000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
61000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-235000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
458000

Files In Submission

Name View Source Status
0001558370-22-004018-index-headers.html Edgar Link pending
0001558370-22-004018-index.html Edgar Link pending
0001558370-22-004018.txt Edgar Link pending
0001558370-22-004018-xbrl.zip Edgar Link pending
drio-20211231.xsd Edgar Link pending
drio-20211231x10k.htm Edgar Link pending
drio-20211231x10k008.jpg Edgar Link pending
drio-20211231x10k_htm.xml Edgar Link completed
drio-20211231xex21d1.htm Edgar Link pending
drio-20211231xex23d1.htm Edgar Link pending
drio-20211231xex31d1.htm Edgar Link pending
drio-20211231xex31d2.htm Edgar Link pending
drio-20211231xex32d1.htm Edgar Link pending
drio-20211231_cal.xml Edgar Link unprocessable
drio-20211231_def.xml Edgar Link unprocessable
drio-20211231_lab.xml Edgar Link unprocessable
drio-20211231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending